Related Experiment Video

Updated: Aug 6, 2025

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
07:04

Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology

Published on: May 2, 2025

468

PD-1 Blockade Falls Short (Repeatedly) in Prostate Cancer

    Cancer Discovery
    |March 17, 2023
    PubMed

    Insights

    Pembrolizumab, a PD-1 inhibitor, failed in late-stage prostate cancer trials. New strategies are essential to improve checkpoint blockade efficacy in the immune-suppressed tumor microenvironment of prostate cancer.

    Area of Science:

    • Oncology
    • Immunotherapy
    • Prostate Cancer Research

    Background:

    • Prostate cancer is often characterized by an immune-suppressed tumor microenvironment.
    • Immune checkpoint inhibitors, such as PD-1 inhibitors, have shown promise in other cancers but have faced challenges in prostate cancer.

    Purpose of the Study:

    • To analyze the outcomes of late-stage clinical trials for pembrolizumab in prostate cancer.
    • To identify the need for novel therapeutic strategies to overcome treatment resistance in prostate cancer.

    Main Methods:

    • Review of late-stage clinical trial data for pembrolizumab in advanced prostate cancer patients.
    • Analysis of factors contributing to treatment failure in the context of the prostate tumor microenvironment.

    Main Results:

    • All late-stage clinical trials evaluating pembrolizumab in men with prostate cancer have resulted in treatment failure.
    • These failures highlight the limitations of current PD-1 inhibitor therapy in this patient population.

    Conclusions:

    • Current checkpoint blockade strategies are insufficient for treating prostate cancer due to the tumor's immune-suppressed nature.
    • Development of innovative treatment approaches is crucial to enhance the effectiveness of immunotherapy in prostate cancer.

    More Related Videos

    MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent06:54

    MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

    Published on: September 3, 2013

    11.3K
    Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction10:18

    Author Spotlight: Magnetic Fluorescent Bead-Based Dual-Reporter Flow Analysis of PDL1-Vaxx Peptide Vaccine-Induced Antibody Blockade of the PD-1/PD-L1 Interaction

    Published on: July 7, 2023

    1.3K

    Related Concept Videos

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

    Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

    Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
    TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
    222
    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

    Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

    Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
    These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
    236
    Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

    Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

    α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
    α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally,...
    904
    Parkinson's Disease: Treatment01:24

    Parkinson's Disease: Treatment

    Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
    Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
    323
    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors01:28

    Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors

    Phosphodiesterase 5 (PDE5) inhibitors are potent enzymes that function to hydrolyze cyclic nucleotides to their corresponding 5' monophosphates. Their unique biochemical properties have been applied in treating Pulmonary Arterial Hypertension (PAH).
    Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...
    210